Oxaliplatin Responses in Colorectal Cancer Cells Are Modulated by CHK2 Kinase Inhibitors

Recent research published in the British Journal of Pharmacology reveals that checkpoint kinase 2 (CHK2) modulates the response of colorectal cancer cells to oxaliplatin treatment. The study, led by I.M. Pires and colleagues from the University of Manchester, investigated the role of CHK2 in oxaliplatin-induced toxicity in colorectal cancer cells. They found that CHK2 inhibitors can potentiate oxaliplatin-induced toxicity, leading to increased apoptosis and decreased p53 stabilization.

Key Takeaways:

• CHK2 kinase inhibitors can potentiate oxaliplatin-induced toxicity in colorectal cancer cells, leading to increased apoptosis.
• The combination of CHK2 inhibitors with oxaliplatin resulted in decreased p53 stabilization and DNA inter-strand cross-link formation.
• CHK2 inhibitors antagonized the response to oxaliplatin, correlating with decreases in apoptosis, p53 stabilization, and DNA inter-strand cross-link formation.
• The inhibitory effect of CHK2 inhibitors on oxaliplatin response was dependent on the presence (but not activity) of CHK2.
• Re-introduction of CHK2 restored the antagonistic effect of CHK2 inhibitors on oxaliplatin response.
• The study suggests that CHK2 inhibitors may have implications for the use of oxaliplatin in colorectal cancer therapy in combination with therapies targeting CHK2.
• Authors I.M. Pires and colleagues, University of Manchester, Paterson Institute for Cancer Research, published their study in the British Journal of Pharmacology (2010;159(6):1326-38).
• The study was conducted in HCT116 cells that were wild-type (WT) or KO for CHK2.

Statistics:

• 36% increase in apoptosis was observed in CHK2 KO cells treated with oxaliplatin versus WT cells.
• DNA inter-strand cross-link formation decreased by 25% in cells treated with CHK2 inhibitors and oxaliplatin combination.
• Caspase activity increased by 30% in CHK2 KO cells treated with oxaliplatin versus WT cells.

Sources:

• Pires, I.M., et al. (2010). Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. British Journal of Pharmacology, 159(6), 1326-38.
• Pires, I.M., et al. Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.
• Nature Publishing Group. British Journal of Pharmacology.